2025年8月16日，新诺威(300765.SZ)发布2025年半年度报告。截至2025年8月15日，共有71个机构投资 者披露持有新诺威A股股份，合计持股量达11.94亿股，占新诺威总股本的85.00%。其中，前十大机构 投资者包括石药集团恩必普药业有限公司、香港中央结算有限公司、中国工商银行股份有限公司-中欧 医疗健康混合型证券投资基金、中国建设银行股份有限公司-工银瑞信前沿医疗股票型证券投资基金、 石药集团欧意药业有限公司、中信建投证券股份有限公司、中国建设银行股份有限公司-汇添富创新医 药主题混合型证券投资基金、中国工商银行股份有限公司-易方达创业板交易型开放式指数证券投资基 金、华泰优逸五号混合型养老金产品-中国银行股份有限公司、中国工商银行股份有限公司-中欧医疗创 新股票型证券投资基金，前十大机构投资者合计持股比例达81.64%。相较于上一季度，前十大机构持 股比例合计上涨了1.63个百分点。 外资态度来看，本期较上一期持股增加的外资基金共计1个，即香港中央结算有限公司，持股增加占比 达0.36%。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 公募基金方面，本期较上一期 ...

Core Viewpoint - The article discusses the recent performance of the A-share market, highlighting a recovery in the Shanghai Composite Index after a political bureau meeting that released positive signals for the economy and investment opportunities in the innovative pharmaceutical sector [1][2][8]. Group 1: A-share Market Performance - The A-share market experienced a pullback but rebounded in the afternoon, with the Shanghai Composite Index closing in the green, reaching a new high for the year [2][7]. - The market showed significant structural differentiation, with consumer and banking sectors rising while technology and new energy sectors faced declines [6][7]. - The trading volume exceeded 1.84 trillion yuan, indicating active market participation [5]. Group 2: Political Bureau Meeting Insights - The Central Political Bureau meeting emphasized the need to "stably resolve local government debt risks" and introduced a roadmap for "clearing financing platforms," alleviating systemic risk concerns [9]. - The meeting also highlighted the importance of stimulating domestic demand and implementing actions to boost consumption, positively impacting sectors like tourism, retail, and food and beverage [10]. - A focus on technological innovation was reiterated, aiming to foster new competitive industries and integrate technological advancements with industrial development [12]. Group 3: Investment Opportunities in Innovative Pharmaceuticals - A significant number of funds have achieved over 100% returns this year, particularly in the innovative pharmaceutical sector, with several funds listed showing substantial year-to-date performance [17]. - Fund managers suggest a cautious yet optimistic approach to the innovative pharmaceutical sector, advising investors to match risk and return expectations and avoid excessive chasing of high-flying stocks [18][19]. - Key guidelines for selecting funds include focusing on long-term performance stability, understanding investment strategies, and aligning with personal risk preferences [20].

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug funds in the public fund rankings, driven by the pharmaceutical market, with a recommendation to seize investment opportunities in innovative drugs [1][2] - As of June 16, the average return of public funds is 3.16%, with stock and mixed funds yielding 3.64% and 4.5% respectively, while several pharmaceutical funds have significantly outperformed these averages [1] - Notable pharmaceutical funds include Changcheng Pharmaceutical Industry Selected Mixed Fund A with a return of 87.11% and Yongying Pharmaceutical Innovation Selected Mixed Fund A with 80.21% [1] Group 2 - The A-share pharmaceutical sector index has increased by 8.09% this year, while the innovative drug sector index has surged nearly 23%, indicating a robust market for innovative drugs [1] - Industry experts suggest that investors should focus on risk matching, valuation changes, and long-term planning when investing in innovative drugs [2] - Recent policy signals and a record number of innovative drug approvals in the first five months of the year indicate a favorable environment for the innovative drug sector, particularly in Hong Kong [2]